Danofran T3A

Danofran T3A may be available in the countries listed below.

Ingredient matches for Danofran T3A

Ondansetron

Ondansetron is reported as an ingredient of Danofran T3A in the following countries:

• Romania

International Drug Name Search

Dreisacarb

Dreisacarb may be available in the countries listed below.

Ingredient matches for Dreisacarb

Calcium Carbonate

Calcium Carbonate is reported as an ingredient of Dreisacarb in the following countries:

• Austria


• Germany

International Drug Name Search

Arpon

Arpon may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Arpon

Cypermethrin

Cypermethrin is reported as an ingredient of Arpon in the following countries:

• Portugal

International Drug Name Search

Muco Mepha

Muco-Mepha may be available in the countries listed below.

Ingredient matches for Muco-Mepha

Acetylcysteine

Acetylcysteine is reported as an ingredient of Muco-Mepha in the following countries:

• Estonia


• Latvia


• Lithuania


• Switzerland

International Drug Name Search

Fatidin

Fatidin may be available in the countries listed below.

Ingredient matches for Fatidin

Famotidine

Famotidine is reported as an ingredient of Fatidin in the following countries:

• Portugal

International Drug Name Search

Minesulin

Minesulin may be available in the countries listed below.

Ingredient matches for Minesulin

Nimesulide

Nimesulide is reported as an ingredient of Minesulin in the following countries:

• Poland

International Drug Name Search

Banzel

Generic Name: rufinamide (Oral route)

roo-FIN-a-mide

Commonly used brand name(s)

In the U.S.

• Banzel

Available Dosage Forms:

• Suspension


• Tablet

Therapeutic Class: Anticonvulsant

Uses For Banzel

Rufinamide is used to control seizures (convulsions) that occur with Lennox-Gastaut syndrome (LGS). It works in the brain to prevent seizures. This medicine will not cure LGS and will only control seizures for as long as you continue to take it.

This medicine is available only with your doctor's prescription.

Before Using Banzel

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of rufinamide in children younger than 4 years of age. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of rufinamide in the elderly. However, elderly patients are more likely to have age-related heart, kidney, or liver problems, which may require caution and an adjustment in the dose for patients receiving rufinamide.

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	C	Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

• Ketorolac


• Naproxen

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

• Carbamazepine


• Desogestrel


• Dienogest


• Drospirenone


• Estradiol Cypionate


• Estradiol Valerate


• Ethinyl Estradiol


• Ethynodiol Diacetate


• Etonogestrel


• Lamotrigine


• Levonorgestrel


• Medroxyprogesterone Acetate


• Mestranol


• Norelgestromin


• Norethindrone


• Norgestimate


• Norgestrel


• Phenobarbital


• Phenytoin


• Primidone


• Triazolam


• Valproic Acid

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

• Familial Short QT syndrome (heart rhythm problem)—Should not be used in patients with this condition.

• Heart rhythm problems (e.g., shortened QT interval)—Use with caution. May make this condition worse.

• Liver disease—Use with caution. The effects may be increased because of slower removal of the medicine from the body.

Proper Use of Banzel

Take this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered.

This medicine should come with a Medication Guide. The oral liquid should also come with instructions for use. Read and follow these instructions carefully. Ask your doctor if you have any questions.

It is best to take this medicine with food. The tablets may be taken whole, broken in half, or crushed if needed.

Measure the oral liquid with the oral dosing syringe that comes with the package. Shake the bottle well just before taking each dose.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For oral dosage form (suspension or tablets):
  
  • For seizures:
    
    • Adults—At first, 400 to 800 milligrams (mg) per day, taken in two divided doses. Your doctor may gradually increase your dose if needed. However, the dose is usually not more than 3200 mg per day.
    
    
    • Children 4 years of age and older—Dose is based on body weight and must be determined by your doctor. The starting dose is 10 milligrams (mg) per kilogram (kg) of body weight per day, taken in two divided doses. Your doctor may gradually increase your dose if needed. However, the dose is usually not more than 45 mg/kg/day or 3200 mg per day.
    
    
    • Children younger than 4 years of age—Use and dose must be determined by your doctor.
    
    
  
  

Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Store the oral liquid in an upright position. Use the liquid within 90 days after opening the bottle for the first time. Throw away any unused liquid.

Precautions While Using Banzel

It is very important that your doctor check you or your child's progress at regular visits to make sure this medicine is working properly.

If you or your child develop any unusual or strange thoughts and behavior while taking this medicine, be sure to discuss it with your doctor. Some changes that have occurred in people taking this medicine are like those seen in people who drink too much alcohol. Other changes might be confusion, worsening of depression, hallucinations (seeing, hearing, or feeling things that are not there), suicidal thoughts, and unusual excitement, nervousness, or irritability.

This medicine may cause some people to become dizzy, drowsy, lightheaded, clumsy, unsteady, or less alert than they are normally. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are not alert or able to think or see well.

This medicine may cause serious allergic reactions that may affect several parts of the body (e.g., liver or kidneys). Check with your doctor right away if you or your child have more than one of the following symptoms: fever, dark-colored urine, headache, rash, itching, extra fluid around the face, stomach pain, unusual tiredness, or yellow eyes or skin.

Do not stop taking this medicine without checking first with your doctor. Your doctor may want you to gradually reduce the amount you are using before stopping it completely.

Birth control pills may not work as well while you are using this medicine. To keep from getting pregnant, use another form of birth control together with your birth control pills. Other forms include condoms, diaphragms, or contraceptive foams or jellies.

Tell your doctor if you become pregnant while taking this medicine. Your doctor may want you to join the North American Antiepileptic Drug Pregnancy Registry. The registry is used by pregnant patients who are taking this medicine.

Avoid drinking alcohol while taking this medicine.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Banzel Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

More common

• Dizziness


• shakiness in the legs, arms, hands, or feet


• sleepiness or unusual drowsiness


• trembling or shaking of the hands or feet


• uncontrolled eye movements

Less common

• Attack, assault, or force


• chills


• cough producing mucus


• diarrhea


• difficulty with breathing


• dizziness or lightheadedness


• fear or nervousness


• feeling of constant movement of self or surroundings


• fever


• general feeling of discomfort or illness


• headache


• joint pain


• loss of appetite


• muscle aches and pains


• nausea


• pain or tenderness around the eyes and cheekbones


• rash


• restlessness


• runny nose


• sensation of spinning


• shakiness and unsteady walk


• shivering


• shortness of breath or troubled breathing


• sore throat


• stuffy or runny nose


• sweating


• tightness in the chest


• trouble in walking


• trouble sitting still


• trouble sleeping


• unsteadiness, trembling, or other problems with muscle control or coordination


• unusual tiredness or weakness


• vomiting


• wheezing

Rare

• Black, tarry stools


• bleeding gums


• blood in the urine or stools


• burning while urinating


• chest pain


• difficult or painful urination


• fainting


• frequent urination


• inability to hold urine


• increased urge to urinate during the night


• increased volume of pale, dilute urine


• lower back or side pain


• pale skin


• pinpoint red spots on the skin


• pounding, slow heartbeat


• sore tongue


• sores, ulcers, or white spots on the lips or in the mouth


• swollen glands


• swollen, painful, or tender lymph glands in the neck, armpit, or groin


• troubled breathing with exertion


• unusual bleeding or bruising


• waking to urinate at night

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Blurred vision


• double vision


• seeing double

Less common

• Acid or sour stomach


• back pain


• belching


• change in hearing


• decreased appetite


• difficulty having a bowel movement (stool)


• ear drainage


• earache or pain in the ear


• heartburn


• indigestion


• itching skin


• stomach discomfort, upset, or pain


• upper abdominal or stomach pain

Rare

• Increased appetite

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Banzel side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More Banzel resources

• Banzel Side Effects (in more detail)
• Banzel Use in Pregnancy & Breastfeeding
• Banzel Drug Interactions
• Banzel Support Group
• 3 Reviews for Banzel - Add your own review/rating

• Banzel Prescribing Information (FDA)


• Banzel Consumer Overview


• Banzel Monograph (AHFS DI)


• Banzel MedFacts Consumer Leaflet (Wolters Kluwer)


• Rufinamide Professional Patient Advice (Wolters Kluwer)

Compare Banzel with other medications

• Lennox-Gastaut Syndrome

Cefotaxima La Santé

Cefotaxima La Santé may be available in the countries listed below.

Ingredient matches for Cefotaxima La Santé

Cefotaxime

Cefotaxime is reported as an ingredient of Cefotaxima La Santé in the following countries:

• Colombia

International Drug Name Search

Erdosteine

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

R05CB15

CAS registry number (Chemical Abstracts Service)

0084611-23-4

Chemical Formula

C8-H11-N-O4-S2

Molecular Weight

249

Therapeutic Category

Mucolytic agent

Chemical Names

({2-Oxo-2-[(2-oxothiolan-3-yl)amino]ethyl)sulfanyl}acetic acid (BAN)

(±)-[[[(Tetrahydro-2-oxo-3-thienyl)carbamoyl]methyl]thio]acetic acid

Foreign Names

• Erdosteinum (Latin)
• Erdostein (German)
• Erdostéine (French)
• Erdosteína (Spanish)

Generic Names

• Erdosteine (OS: BAN)
• Erdostéine (OS: DCF)
• Dithiosteine (IS)
• RV 144 (IS)

Brand Names

• Biopulmin
  Grünenthal, Chile



• Dostol
  Grünenthal, Peru



• Ectrin
  OEP, Philippines



• Edotin
  Ferron, Indonesia



• Erdomed
  CSC, Austria; CSC, Hungary; CSC, Romania; Edmond, Bulgaria; Medicom, Czech Republic; Medicom, Slovakia



• Erdopect
  Orion, Finland



• Erdostin
  Sandoz, Turkey



• Erdotin
  ASTA Medica, Brazil; Edmond, Italy; Galen, United Kingdom; Galen, Ireland; Edmond Pharma S.r.lIT, Denmark



• Esteclin
  Syntex, Mexico



• Fluidasa
  Montpellier, Argentina



• Ilvico
  Galen, Ireland



• Mucofor
  Vifor, Switzerland



• Mucotec
  Hikma, United Arab Emirates; Hikma, Bahrain; Hikma, Egypt; Hikma, Iraq; Hikma, Jordan; Hikma, Kuwait; Hikma, Lebanon; Hikma, Libya; Hikma, Oman; Hikma, Qatar; Hikma, Saudi Arabia; Hikma, Sudan; Hikma, Syria; Hikma, Yemen



• Mucothera
  Therabel, Luxembourg



• Recustein
  Landson, Indonesia



• Tantong
  Xian Haixin, China



• Vectrine
  Dexa Medica, Indonesia; Dexa Medica, Vietnam; Pharma 2000, France



• Zertin
  GlaxoSmithKline, Philippines

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Pilopine HS

Pilopine HS is a brand name of pilocarpine ophthalmic, approved by the FDA in the following formulation(s):

PILOPINE HS (pilocarpine hydrochloride - gel; ophthalmic)

• 
  Manufacturer: ALCON
  
  Approval date: October 1, 1984
  
  Strength(s): 4% ^[RLD]

Has a generic version of Pilopine HS been approved?

No. There is currently no therapeutically equivalent version of Pilopine HS available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pilopine HS. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Pilopine HS.

See also...

• Pilopine HS Gel Consumer Information (Wolters Kluwer)
• Pilopine-HS Consumer Information (Cerner Multum)
• Pilopine-HS Advanced Consumer Information (Micromedex)
• Pilocarpine Drops Consumer Information (Wolters Kluwer)
• Pilocarpine Gel Consumer Information (Wolters Kluwer)
• Piloptic Drops Consumer Information (Wolters Kluwer)
• Pilocarpine ophthalmic Consumer Information (Cerner Multum)
• Minims Pilocarpine 2% Advanced Consumer Information (Micromedex)
• Minims Pilocarpine 4% Advanced Consumer Information (Micromedex)
• Ocusert Pilo Advanced Consumer Information (Micromedex)
• Pilocarpine Ophthalmic Advanced Consumer Information (Micromedex)
• Pilocarpine AHFS DI Monographs (ASHP)
• Pilocarpine Hydrochloride AHFS DI Monographs (ASHP)

Remedeine

Remedeine may be available in the countries listed below.

UK matches:

• Remedeine and Remedeine forte tablets
• Remedeine and Remedeine forte tablets (SPC)

Ingredient matches for Remedeine

Dihydrocodeine

Dihydrocodeine tartrate (a derivative of Dihydrocodeine) is reported as an ingredient of Remedeine in the following countries:

• United Kingdom

Paracetamol

Paracetamol is reported as an ingredient of Remedeine in the following countries:

• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Econazole Sopharma

Econazole Sopharma may be available in the countries listed below.

Ingredient matches for Econazole Sopharma

Econazole

Econazole nitrate (a derivative of Econazole) is reported as an ingredient of Econazole Sopharma in the following countries:

• Bulgaria

International Drug Name Search

Halotestin

In the US, Halotestin (fluoxymesterone systemic) is a member of the following drug classes: androgens and anabolic steroids, hormones/antineoplastics and is used to treat Breast Cancer, Breast Cancer - Palliative, Delayed Puberty - Male, Hypogonadism - Male and Postmenopausal Symptoms.

US matches:

• Halotestin

Ingredient matches for Halotestin

Fluoxymesterone

Fluoxymesterone is reported as an ingredient of Halotestin in the following countries:

• Ghana


• Kenya


• Liberia


• Sierra Leone


• Tanzania


• Uganda


• Zimbabwe

International Drug Name Search

Huminsulin 30 / 70

Huminsulin 30/70 may be available in the countries listed below.

Ingredient matches for Huminsulin 30/70

Insulin Injection, Biphasic Isophane

Insulin Injection, Biphasic Isophane human (a derivative of Insulin Injection, Biphasic Isophane) is reported as an ingredient of Huminsulin 30/70 in the following countries:

• India

International Drug Name Search

Galzin

In the US, Galzin (zinc acetate systemic) is a member of the drug class minerals and electrolytes and is used to treat Wilson's Disease and Zinc Deficiency.

US matches:

• Galzin

Ingredient matches for Galzin

Zinc Acetate

Zinc Acetate is reported as an ingredient of Galzin in the following countries:

• United States

International Drug Name Search

Mucovix

Mucovix may be available in the countries listed below.

Ingredient matches for Mucovix

Ambroxol

Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Mucovix in the following countries:

• Greece

International Drug Name Search

Paliperidone

In the US, Paliperidone (paliperidone systemic) is a member of the drug class atypical antipsychotics and is used to treat Bipolar Disorder, Depression, Schizoaffective Disorder and Schizophrenia.

US matches:

• Paliperidone


• Paliperidone Extended-Release Tablets


• Paliperidone Intramuscular

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

N05AX13

CAS registry number (Chemical Abstracts Service)

0144598-75-4

Chemical Formula

C23-H27-F-N4-O3

Molecular Weight

426

Therapeutic Categories

Neuroleptic

Dopamine D2 antagonist

Chemical Names

(RS)-3-{2-[4-(6-Fluor-1,2-benzisoxazol-3-yl)piperidino]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-on (IUPAC)

(±)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (WHO)

Foreign Names

• Paliperidonum (Latin)
• Paliperidon (German)
• Paliperidone (French)
• Paliperidona (Spanish)

Generic Names

• Paliperidone (OS: USAN)
• 9-Hydroxyrisperidone (IS)
• ELAN C3 (IS)
• R-76477 (IS: JohnsonJohns)
• RO-92670 (IS)

Brand Names

• Invega Sustenna
  Johnson & Johnson, United States



• Invega
  Janssen, Australia; Janssen, Germany; Janssen, Spain; Janssen, Greece; Janssen, Hungary; Janssen, Ireland; Janssen, Italy; Janssen, Luxembourg; Janssen, Netherlands; Janssen-Cilag, Switzerland; Janssen-Cilag, Denmark; Janssen-Cilag, United Kingdom; Janssen-Cilag, Indonesia; Janssen-Cilag, Singapore; Janssen-Cilag International, Austria; Janssen-Ortho Inc., Canada; Johnson & Johnson, Croatia (Hrvatska); Ortho-McNeil, United States; Xian-Janssen, China



• INVEGA
  Janssen-Cilag, Sweden

International Drug Name Search

Glossary

IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Ethosuximide

In some countries, this medicine may only be approved for veterinary use.

In the US, Ethosuximide (ethosuximide systemic) is a member of the drug class succinimide anticonvulsants and is used to treat Seizures.

US matches:

• Ethosuximide


• Ethosuximide Solution


• Ethosuximide Oral Solution


• Ethosuximide Syrup

UK matches:

• Ethosuximide 250mg Capsules (SPC)

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

N03AD01

CAS registry number (Chemical Abstracts Service)

0000077-67-8

Chemical Formula

C7-H11-N-O2

Molecular Weight

141

Therapeutic Category

Antiepileptic agent

Chemical Name

2,5-Pyrrolidinedione, 3-ethyl-3-methyl-

Foreign Names

• Ethosuximidum (Latin)
• Ethosuximid (German)
• Ethosuximide (French)
• Etosuximida (Spanish)

Generic Names

• Ethosuximide (OS: USAN, BAN)
• Éthosuximide (OS: DCF)
• Etosuccimide (OS: DCIT)
• Atysmal (IS)
• Mesentol (IS)
• Pemal (IS)
• Suxin (IS)
• Thilopemal (IS)
• Ethosuximid (PH: Ph. Eur. 6)
• Ethosuximide (PH: BP 2010, Ph. Eur. 6, Ph. Int. 4, USP 32, JP XV)
• Ethosuximidum (PH: Ph. Int. 4, Ph. Eur. 6)

Brand Names

• Emeside
  Chemidex, United Kingdom



• Emeside (veterinary use)
  LAB, United Kingdom



• Epileo Petit mal
  Isei, Japan



• Ethosuximide
  Banner Pharmacaps, United States; Covenant, United States; Mikart, United States; Pfizer, India; Pharmaceutical Associates, United States; Teva USA, United States



• Ethymal
  Apotex Europe, Netherlands



• Etosuximida Faes
  Faes, Spain



• Etosuximida
  Bestpharma, Chile



• Fluozoid
  Valdecasas, Mexico



• Petimid
  Osel, Turkey



• Petinimid
  Gerot, Austria; Gerot, Czech Republic; Gerot, Poland; Gerot, Romania; Gerot, Slovakia; Orion, Switzerland



• Petnidan
  Desitin, Germany; Desitin, Hungary; Desitin, Luxembourg; Desitin Pharma, Slovakia; Salus, Slovenia



• Suxilep
  Jenapharm, Bulgaria; Jenapharm, Georgia; Mibe Jena, Germany



• Suxinutin
  Pfizer, Serbia; Pfizer, Sweden



• Zarondan
  Pfizer, Denmark; Pfizer, Iceland



• Zarontin
  Daiichi Sankyo, Japan; Elea, Argentina; Parke Davis, Ireland; Pfizer, Australia; Pfizer, Belgium; Pfizer, France; Pfizer, United Kingdom; Pfizer, Greece; Pfizer, Italy; Pfizer, Luxembourg; Pfizer, New Zealand; Pfizer, Slovenia; Pfizer, United States; Pfizer, South Africa

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
SPC	Summary of Product Characteristics (UK)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Kalium Verla

Kalium Verla may be available in the countries listed below.

Ingredient matches for Kalium Verla

Potassium Citrate

Potassium Citrate is reported as an ingredient of Kalium Verla in the following countries:

• Germany

International Drug Name Search

Modrex

Modrex may be available in the countries listed below.

Ingredient matches for Modrex

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Modrex in the following countries:

• Bahrain


• Iraq


• Libya


• Qatar


• Saudi Arabia


• Sudan


• United Arab Emirates


• Yemen

International Drug Name Search

Carbaltpsin

Carbaltpsin may be available in the countries listed below.

Ingredient matches for Carbaltpsin

Carbamazepine

Carbamazepine is reported as an ingredient of Carbaltpsin in the following countries:

• Russian Federation

International Drug Name Search

Flosin

Flosin may be available in the countries listed below.

Ingredient matches for Flosin

Tamsulosin

Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Flosin in the following countries:

• Hungary


• Latvia


• Lithuania

International Drug Name Search

Kenhancer

Kenhancer may be available in the countries listed below.

Ingredient matches for Kenhancer

Ketoprofen

Ketoprofen is reported as an ingredient of Kenhancer in the following countries:

• Singapore

International Drug Name Search

Limember

Limember may be available in the countries listed below.

Ingredient matches for Limember

Memantine

Memantine hydrochloride (a derivative of Memantine) is reported as an ingredient of Limember in the following countries:

• Peru

International Drug Name Search

Fexofast

Fexofast may be available in the countries listed below.

Ingredient matches for Fexofast

Fexofenadine

Fexofenadine hydrochloride (a derivative of Fexofenadine) is reported as an ingredient of Fexofast in the following countries:

• South Africa

International Drug Name Search

Mylepsin

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Mylepsin

Primidone

Primidone is reported as an ingredient of Mylepsin in the following countries:

• United States

International Drug Name Search

Loperdium

Loperdium may be available in the countries listed below.

Ingredient matches for Loperdium

Loperamide

Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Loperdium in the following countries:

• Bangladesh

International Drug Name Search

Midodrine Hydrochloride

Ingredient matches for Midodrine Hydrochloride

Midodrine

Midodrine Hydrochloride (BANM, JAN, USAN) is known as Midodrine in the US.

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)
JAN	Japanese Accepted Name
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

BB-K8

BB-K8 may be available in the countries listed below.

Ingredient matches for BB-K8

Amikacin

Amikacin sulfate (a derivative of Amikacin) is reported as an ingredient of BB-K8 in the following countries:

• Italy

International Drug Name Search

Algoflex

Algoflex may be available in the countries listed below.

Ingredient matches for Algoflex

Ibuprofen

Ibuprofen is reported as an ingredient of Algoflex in the following countries:

• Hungary

Ketoprofen

Ketoprofen is reported as an ingredient of Algoflex in the following countries:

• Hungary

International Drug Name Search

Hedix

Hedix may be available in the countries listed below.

Ingredient matches for Hedix

Diazepam

Diazepam is reported as an ingredient of Hedix in the following countries:

• Indonesia

Metamizole

Metamizole is reported as an ingredient of Hedix in the following countries:

• Indonesia

International Drug Name Search

PMS-Amiodarone

PMS-Amiodarone may be available in the countries listed below.

Ingredient matches for PMS-Amiodarone

Amiodarone

Amiodarone hydrochloride (a derivative of Amiodarone) is reported as an ingredient of PMS-Amiodarone in the following countries:

• Canada

International Drug Name Search

Fiacin

Fiacin may be available in the countries listed below.

Ingredient matches for Fiacin

Indometacin

Indometacin is reported as an ingredient of Fiacin in the following countries:

• Spain

Prednisone

Prednisone is reported as an ingredient of Fiacin in the following countries:

• Spain

International Drug Name Search

Metakelfin

Metakelfin may be available in the countries listed below.

Ingredient matches for Metakelfin

Pyrimethamine

Pyrimethamine is reported as an ingredient of Metakelfin in the following countries:

• Italy

International Drug Name Search

ASS AL

ASS AL may be available in the countries listed below.

Ingredient matches for ASS AL

Aspirin

Acetylsalicylic Acid is reported as an ingredient of ASS AL in the following countries:

• Germany

International Drug Name Search

Bonalfa SP

Bonalfa SP may be available in the countries listed below.

Ingredient matches for Bonalfa SP

Tacalcitol

Tacalcitol is reported as an ingredient of Bonalfa SP in the following countries:

• Peru

International Drug Name Search

Miconaft

Miconaft may be available in the countries listed below.

Ingredient matches for Miconaft

Tolnaftate

Tolnaftate is reported as an ingredient of Miconaft in the following countries:

• Romania

International Drug Name Search

Anephylline M

Anephylline M may be available in the countries listed below.

Ingredient matches for Anephylline M

Diprophylline

Diprophylline is reported as an ingredient of Anephylline M in the following countries:

• Japan

International Drug Name Search

Zofran

See also: Generic Zofran ODT

Zofran is a brand name of ondansetron, approved by the FDA in the following formulation(s):

ZOFRAN (ondansetron hydrochloride - injectable; injection)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: January 4, 1991
  
  Strength(s): EQ 2MG BASE/ML ^[RLD][AP]

ZOFRAN (ondansetron hydrochloride - solution; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: January 24, 1997
  
  Strength(s): EQ 4MG BASE/5ML ^[RLD][AA]

ZOFRAN (ondansetron hydrochloride - tablet; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: December 31, 1992
  
  Strength(s): EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: August 27, 1999
  
  Strength(s): EQ 24MG BASE ^[RLD][AB]

Has a generic version of Zofran been approved?

A generic version of Zofran has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zofran and have been approved by the FDA:

ondansetron hydrochloride injectable; injection

• 
  Manufacturer: APOTEX
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: APP PHARMS
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: BAXTER HLTHCARE
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: BEDFORD
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: EMCURE PHARMS
  
  Approval date: April 16, 2010
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: GLAND PHARMA LTD
  
  Approval date: September 25, 2009
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: HIKMA FARMACEUTICA
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: HOSPIRA
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: HOSPIRA
  
  Approval date: January 19, 2007
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: LANNETT
  
  Approval date: April 14, 2010
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: LANNETT
  
  Approval date: August 5, 2010
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: LUITPOLD
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: LUITPOLD
  
  Approval date: November 18, 2008
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: PFIZER
  
  Approval date: April 23, 2008
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: PLIVA HRVATSKA DOO
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: SANDOZ
  
  Approval date: June 27, 2007
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: SPECTRUM PHARMS
  
  Approval date: March 26, 2007
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: SUN PHARM INDS (IN)
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: TEVA
  
  Approval date: November 22, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: WOCKHARDT
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]

ondansetron hydrochloride solution; oral

• 
  Manufacturer: AMNEAL PHARMS
  
  Approval date: January 31, 2011
  
  Strength(s): EQ 4MG BASE/5ML ^[AA]


• 
  Manufacturer: APOTEX
  
  Approval date: June 25, 2007
  
  Strength(s): EQ 4MG BASE/5ML ^[AA]


• 
  Manufacturer: AUROBINDO PHARMA
  
  Approval date: November 28, 2007
  
  Strength(s): EQ 4MG BASE/5ML ^[AA]


• 
  Manufacturer: ROXANE
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 4MG BASE/5ML ^[AA]


• 
  Manufacturer: SILARX
  
  Approval date: January 27, 2011
  
  Strength(s): EQ 4MG BASE/5ML ^[AA]


• 
  Manufacturer: TARO
  
  Approval date: November 30, 2007
  
  Strength(s): EQ 4MG BASE/5ML ^[AA]

ondansetron hydrochloride tablet; oral

• 
  Manufacturer: APOTEX
  
  Approval date: June 25, 2007
  
  Strength(s): EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: AUROBINDO PHARMA
  
  Approval date: July 31, 2007
  
  Strength(s): EQ 24MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 24MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: GLENMARK GENERICS
  
  Approval date: June 25, 2007
  
  Strength(s): EQ 24MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: June 25, 2007
  
  Strength(s): EQ 24MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: NATCO PHARMA LTD
  
  Approval date: June 25, 2007
  
  Strength(s): EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: PAR PHARM
  
  Approval date: June 25, 2007
  
  Strength(s): EQ 24MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: PLIVA HRVATSKA DOO
  
  Approval date: June 25, 2007
  
  Strength(s): EQ 24MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: June 25, 2007
  
  Strength(s): EQ 24MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: SUN PHARM INDS (IN)
  
  Approval date: June 25, 2007
  
  Strength(s): EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: TARO
  
  Approval date: March 28, 2011
  
  Strength(s): EQ 24MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: TEVA
  
  Approval date: June 25, 2007
  
  Strength(s): EQ 24MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]


• 
  Manufacturer: WEST WARD
  
  Approval date: September 6, 2007
  
  Strength(s): EQ 24MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 8MG BASE ^[AB]

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (ondansetron hydrochloride injectable; injection)

• 
  Manufacturer: APOTEX INC
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: APP PHARMS
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: BAXTER HLTHCARE
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: BEDFORD LABS
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: HIKMA FARMACEUTICA
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: HOSPIRA
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: LUITPOLD
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: LUITPOLD
  
  Approval date: November 18, 2008
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: PFIZER
  
  Approval date: April 23, 2008
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: SANDOZ
  
  Approval date: June 27, 2007
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: SUN PHARM INDS LTD
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: TARO PHARMS IRELAND
  
  Approval date: March 21, 2008
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: TEVA
  
  Approval date: November 22, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]


• 
  Manufacturer: WOCKHARDT
  
  Approval date: December 26, 2006
  
  Strength(s): EQ 2MG BASE/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zofran. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Process and composition using ondansetron
  Patent 5,344,658
  Issued: September 6, 1994
  Inventor(s): Collin; David T.
  Assignee(s): Glaxo Group Limited
  The invention relates to a process for reducing the crystal size of ondansetron hydrochloride dihydrate produced by crystallisation from solvent to a size which is suitable for effective distribution in a tablet blend, in particular 100% less that 250 .mu.m. The ondansetron hydrochloride dihydrate is desolvated by drying at elevated temperature and reduced or atmospheric pressure and is then rehydrated.
  
  Patent expiration dates:
  
  
  • September 6, 2011
    
  
  
  
  • March 6, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Oral compositions containing ondansetron
  Patent 5,854,270
  Issued: December 29, 1998
  Inventor(s): Gambhir; Renu
  Assignee(s): Glaxo Wellcome Inc.
  The invention relates to a liquid composition for oral administration comprising ondansetron or a pharmaceutically acceptable derivative thereof, a sweetener and one or more pharmaceutically acceptable excipients. The sweetener comprises one or more polyhydric alcohols and the pH of the combination lies in the range 2.0 to 5.0. Methods for the manufacture of such compositions and for their use in the treatment of conditions mediated through the action of 5-hydroxytryptamine (5 HT) at 5 HT.sub.3 receptors are also included.
  
  Patent expiration dates:
  
  
  • November 20, 2015
    
    ✓ 
    Patent use: RELIEF OF NAUSEA AND VOMITING
    ✓ 
    Drug product
  
  
  
  • May 20, 2016
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Zofran Consumer Information (Drugs.com)
• Zofran Consumer Information (Wolters Kluwer)
• Zofran Solution Consumer Information (Wolters Kluwer)
• Zofran Tablets Consumer Information (Wolters Kluwer)
• Zofran Consumer Information (Cerner Multum)
• Zofran injection Consumer Information (Cerner Multum)
• Zofran Advanced Consumer Information (Micromedex)
• Zofran Oral, Oromucosal Advanced Consumer Information (Micromedex)
• Zofran AHFS DI Monographs (ASHP)
• Ondansetron Consumer Information (Drugs.com)
• Ondansetron Consumer Information (Wolters Kluwer)
• Ondansetron Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Ondansetron Soluble Film Consumer Information (Wolters Kluwer)
• Ondansetron Solution Consumer Information (Wolters Kluwer)
• Ondansetron Tablets Consumer Information (Wolters Kluwer)
• Ondansetron Consumer Information (Cerner Multum)
• Ondansetron injection Consumer Information (Cerner Multum)
• Ondansetron Oral, Injection, Intravenous Advanced Consumer Information (Micromedex)
• Ondansetron Oral, Oromucosal Advanced Consumer Information (Micromedex)
• Ondansetron Hydrochloride AHFS DI Monographs (ASHP)

Ulceral

Ulceral may be available in the countries listed below.

Ingredient matches for Ulceral

Omeprazole

Omeprazole is reported as an ingredient of Ulceral in the following countries:

• Spain

International Drug Name Search

Morphex CR

Morphex CR may be available in the countries listed below.

Ingredient matches for Morphex CR

Morphine

Morphine hydrochloride (a derivative of Morphine) is reported as an ingredient of Morphex CR in the following countries:

• Israel

International Drug Name Search

Istalol

In the US, Istalol (timolol ophthalmic) is a member of the drug class ophthalmic glaucoma agents and is used to treat Glaucoma - Open Angle and Intraocular Hypertension.

US matches:

• Istalol


• Istalol Drops

Ingredient matches for Istalol

Timolol

Timolol maleate (a derivative of Timolol) is reported as an ingredient of Istalol in the following countries:

• United States

International Drug Name Search

Rocephin

Generic Name: Ceftriaxone Sodium
Class: Third Generation Cephalosporins
VA Class: AM117
Chemical Name: [6R-[6α,7β(Z)]]-7-[[(2-Amino-4-thiazolyl) (methoxyimino)acetyl]amino] - 8 - oxo - 3 - [[(1,2,5,6 - tetrahydro - 2 - methyl - 5,6 - dioxo - 1,2,4 - triazin - 3 - yl)thio]methyl] - 5 - thia - 1 - azabicyclo[4.2.0]octo - 2 - ene - 2 - carboxylic acid disodium salt
CAS Number: 74578-69-1

Introduction

Antibacterial; β-lactam antibiotic; third generation cephalosporin.^{1 16 104 105 106 165 171}

Uses for Rocephin

Acute Otitis Media (AOM)

Treatment of AOM caused by S. pneumoniae, H. influenzae (including β-lactamase-producing strains), or Moraxella catarrhalis (including β-lactamase-producing strains).^{1 310 311 312 313 427 428 429 458 494} The single-dose IM ceftriaxone regimen has some practical advantages (ensures compliance, can be used in patients with nausea and vomiting),^{311 312 430 494} but manufacturer cautions that clinical cure rate with the single-dose regimen may be lower than that reported with multiple-dose regimens of oral anti-infectives usually used for AOM.¹

Treatment of persistent or recurrent AOM† in pediatric patients ≥3 months of age with infections that failed to respond to other anti-infectives (e.g., amoxicillin, amoxicillin and clavulanate potassium, cefaclor, cefuroxime).^{486 487}

Bone and Joint Infections

Treatment of bone and joint infections (e.g., osteomyelitis, septic arthritis) caused by susceptible Staphylococcus aureus, Streptococcus pneumoniae, Enterobacter, Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.^{1 87 104 121 124 127 131 132 150 246}

Endocarditis

Treatment of native valve or prosthetic valve endocarditis caused by viridans streptococci (e.g., S. oralis, S. milleri group, S. mitis, S. mutans, S. salivarius, S. sanguis) or S. bovis (nonenterococcal group D streptococcus)†.^{413 414 415 416 417 491 500} Used for endocarditis caused by viridans streptococci or S. bovis highly susceptible to penicillin (penicillin MIC ≤0.12 mcg/mL) or relatively resistant to penicillin (penicillin MIC >0.12 mcg/mL but ≤0.5 mcg/mL).⁴¹³ Should not be used for endocarditis caused by viridans streptococci or S. bovis highly resistant to penicillin (penicillin MIC >0.5 mcg/mL) or caused by Abiotrophia defectiva, Granulicatella, or Gamella.⁴¹³

Treatment of native valve or prosthetic valve endocarditis caused by slow-growing fastidious gram-negative bacilli termed the HACEK group† (i.e., Haemophilus parainfluenzae, H. aphrophilus, H. paraphrophilus, H. influenzae, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae, K. denitrificans).⁴¹³

Not usually recommended for treatment of endocarditis caused by Enterococcus (e.g., E. faecalis, E. faecium).⁴¹³ May be used in conjunction with ampicillin and sulbactam for treatment of native or prosthetic valve endocarditis caused by E. faecalis resistant to penicillin, aminoglycosides, and vancomycin when there are few therapeutic options.⁴¹³ Since treatment of enterococcal endocarditis caused by vancomycin-resistant or multidrug-resistant enterococci is complex, consult specialists in infectious disease, cardiology, cardiac surgery, and microbiology.⁴¹³

Not indicated for treatment of staphylococcal endocarditis.⁴¹³

Alternative for prevention of α-hemolytic (viridans group) streptococcal endocarditis† in individuals undergoing certain dental or upper respiratory tract procedures who have cardiac conditions that put them at highest risk of endocarditis.⁵⁰⁹ Oral amoxicillin is usual drug of choice for such prophylaxis;⁵⁰⁹ ceftriaxone (or cefazolin) is an alternative in penicillin-allergic individuals or when an oral anti-infective cannot be used.⁵⁰⁹ Should not be used in those with immediate-type penicillin hypersensitivity (see Cross-hypersensitivity under Cautions).⁵⁰⁹ Consult most recent AHA recommendations for specific information on which cardiac conditions are associated with highest risk of endocarditis and which procedures require prophylaxis.⁵⁰⁹

Intra-abdominal Infections

Treatment of intra-abdominal infections caused by susceptible E. coli, K. pneumoniae, Bacteroides fragilis, Clostridium (not C. difficile), or Peptostreptococcus.^{1 104 105 129 132 149}

Treatment of mixed aerobic-anaerobic intra-abdominal infections;^{149 434} should not be used alone when B. fragilis may be present.^{119 128 434}

Meningitis and Other CNS Infections

Treatment of meningitis caused by susceptible H. influenzae, N. meningitidis, or S. pneumoniae in neonates,^{1 104 140 142 144 243 249 250} children,^{80 87 104 130 139 140 141 142 143 144 187 197 243 245 246 249 250 257 258 259 270 272} or adults.^{80 87 104 138 197 270 271} A drug of choice for meningitis caused by penicillin-resistant S. pneumoniae,^{292 324 329 331 332 334 346 347 349} but consider that S. pneumoniae with reduced susceptibility to cephalosporins have been reported with increasing frequency^{109 111 470 471} and susceptibility can no longer be assumed.^{243 292 323 330 324 344}

Treatment of meningitis and other CNS infections caused by susceptible Enterobacteriaceae† (e.g., E. coli, Klebsiella).^{1 104 133 156}

Should not be used alone for empiric treatment of meningitis when Listeria monocytogenes, enterococci, staphylococci, or Pseudomonas aeruginosa may be involved.^{9 87 137 197 292 400 468}

Empiric treatment of bacterial brain abscesses and other CNS infections (e.g., subdural empyema, intracranial epidural abscesses) caused by gram-positive aerobic cocci, Enterobacteriaceae (e.g., E. coli, Klebsiella), and/or anaerobic bacteria (e.g., Bacteroides, Fusobacterium).^{468 478}

Respiratory Tract Infections

Treatment of respiratory tract infections (including pneumonia) caused by susceptible S. aureus, S. pneumoniae, H. influenzae, H. parainfluenzae, E. aerogenes, E. coli, K. pneumoniae, P. mirabilis, or Serratia marcescens.^{1 87 88 104 105 119 120 121 124 125 127 128 129 131 197 246 313 423 493}

Treatment of community-acquired pneumonia (CAP).⁵¹² Recommended by ATS and IDSA as an alternative for treatment of CAP caused by penicillin-susceptible S. pneumoniae and as a preferred drug for treatment of CAP caused by penicillin-resistant S. pneumoniae, provided in vitro susceptibility has been demonstrated.⁵¹² Also recommended in certain combination regimens used for empiric treatment of CAP.⁵¹² Select regimen for empiric treatment of CAP based on most likely pathogens and local susceptibility patterns; after pathogen is identified, modify to provide more specific therapy (pathogen-directed therapy).⁵¹²

For empiric outpatient treatment of CAP when risk factors for drug-resistant S. pneumoniae are present (e.g., comorbidities such as chronic heart, lung, liver, or renal disease, diabetes, alcoholism, malignancies, asplenia, immunosuppression, use of anti-infectives within the last 3 months), ATS and IDSA recommend monotherapy with a fluoroquinolone active against S. pneumoniae (moxifloxacin, gemifloxacin, levofloxacin) or, alternatively, a combination regimen that includes a β-lactam active against S. pneumoniae (high-dose amoxicillin or fixed combination of amoxicillin and clavulanic acid or, alternatively, ceftriaxone, cefpodoxime, or cefuroxime) given in conjunction with a macrolide (azithromycin, clarithromycin, erythromycin) or doxycycline.⁵¹²

For empiric inpatient treatment of CAP in patients not requiring treatment in an intensive care unit (non-ICU patients), IDSA and ATS recommend monotherapy with a fluoroquinolone (moxifloxacin, gemifloxacin, levofloxacin) or, alternatively, a combination regimen that includes a β-lactam (usually cefotaxime, ceftriaxone, or ampicillin) given in conjunction with a macrolide (azithromycin, clarithromycin, erythromycin).⁵¹² For empiric inpatient treatment of CAP in ICU patients when Pseudomonas and methicillin-resistant S. aureus (MRSA; also known as oxacillin-resistant S. aureus or ORSA) are not suspected, IDSA and ATS recommend a combination regimen that includes a β-lactam (cefotaxime, ceftriaxone, fixed combination of ampicillin and sulbactam) given in conjunction with either azithromycin or a fluoroquinolone (gemifloxacin, levofloxacin, moxifloxacin).⁵¹²

Septicemia

Treatment of septicemia caused by S. aureus, S. pneumoniae, E. coli, H. influenzae, or K. pneumoniae.^{1 87 104 105 120 121 124 125 131 246}

Select anti-infective for treatment of sepsis syndrome based on probable source of infection, gram-stained smears of appropriate clinical specimens, immune status of the patient, and current patterns of bacterial resistance within the hospital and local community.¹⁹⁷ Some clinicians suggest that certain parenteral cephalosporins (i.e., cefepime, cefotaxime, ceftriaxone, ceftazidime) are good choices for treatment of gram-negative sepsis.¹⁹⁷

For initial treatment of life-threatening sepsis in adults, some clinicians suggest that a third or fourth generation cephalosporin (i.e., cefepime, cefotaxime, ceftriaxone, ceftazidime), fixed combination of piperacillin and tazobactam, or a carbapenem (imipenem or meropenem) be used in conjunction with vancomycin with or without an aminoglycoside (amikacin, gentamicin, tobramycin).¹⁹⁷

Skin and Skin Structure Infections

Treatment of skin and skin structure infections caused by susceptible S. aureus, S. epidermidis, S. pyogenes (group A β-hemolytic streptococci), viridans streptococci, E. coli, E. cloacae, K. oxytoca, K. pneumoniae, P. mirabilis, Morganella morganii, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, B. fragilis, or Peptostreptococcus.^{1 87 89 104 105 120 121 124 128 129 131 132}

Urinary Tract Infections (UTIs)

Treatment of complicated and uncomplicated UTIs caused by E. coli, K. pneumoniae, M. morganii, P. mirabilis, or P. vulgaris.^{1 82 91 104 119 120 121 124 125 127 128 129 131 246 455}

Considered a drug of choice for treatment of UTIs caused by susceptible Enterobacteriaceae, including susceptible strains of E. coli, K. pneumoniae, P. rettgeri, M. morganii, P. vulgaris, or P. stuartii; an aminoglycoside usually used concomitantly in severe infections.¹⁹⁷

Ceftriaxone (like other third generation cephalosporins) generally should not be used for treatment of uncomplicated UTIs when other anti-infectives with a narrower spectrum of activity could be used.^{105 106 128 179 446}

Actinomycosis

Has been used for treatment of infections caused by Actinomyces†.^{380 381} Not considered a drug of choice; penicillin G generally preferred for initial treatment of all forms of actinomycosis, including thoracic, abdominal, CNS, and cervicofacial infections.^{197 292 382}

Bartonella Infections

Treatment of bacteremia caused by Bartonella quintana† (in conjunction with oral erythromycin or oral azithromycin).³⁹⁶

The possible role of ceftriaxone in the treatment of infections caused by Bartonella henselae† (e.g., cat scratch disease, bacillary angiomatosis, peliosis hepatitis) has not been determined.⁴⁴³ Cat scratch disease generally is self-limited in immunocompetent individuals and may resolve spontaneously in 2–4 months; some clinicians suggest that anti-infective therapy be considered for acutely or severely ill patients with systemic symptoms, particularly those with hepatosplenomegaly or painful lymphadenopathy, and such therapy probably is indicated in immunocompromised patients.^{292 443 444 445} Anti-infectives also are indicated in patients with B. henselae infections who develop bacillary angiomatosis, neuroretinitis, or Parinaud’s oculoglandular syndrome.^{292 443 444 445}

Optimum regimens for treatment of infections caused by B. quintana or for treatment of cat scratch disease or other B. henselae infections have not been identified.^{197 292 396 442 464 465}

Capnocytophaga Infections

Treatment of infections caused by Capnocytophaga.¹⁹⁷

Optimum regimens for treatment of infections caused by Capnocytophaga have not been identified; some clinicians recommend use of penicillin G^{197 463} or, alternatively, a third generation cephalosporin (cefotaxime, ceftizoxime, ceftriaxone), a carbapenem (imipenem and cilastatin sodium, meropenem), vancomycin, a fluoroquinolone, or clindamycin.¹⁹⁷

Chancroid

Treatment of chancroid† (genital ulcers caused by H. ducreyi).^{167 210 211 229 241 274}

CDC¹⁶⁷ and others²⁴² recommend azithromycin, ceftriaxone, ciprofloxacin or erythromycin as drugs of choice for treatment of chancroid. HIV-infected patients and uncircumcised patients may not respond to treatment as well as those who are HIV-negative or circumcised.^{167 202 241 242} CDC recommends that the single-dose ceftriaxone regimen be used in HIV patients only if follow-up can be ensured.¹⁶⁷

Gonorrhea and Associated Infections

Treatment of uncomplicated cervical, urethral, or rectal infections caused by susceptible N. gonorrhoeae.^{1 167 242 273 274 292 336 508} Recommended by CDC, AAP, and others as a drug of choice for uncomplicated gonorrhea in adults, adolescents, and children.^{167 242 273 292 508}

Treatment of pharyngeal infections caused by N. gonorrhoeae.^{115 118 167 242 273 292 508} Recommended by CDC, AAP, and others as the regimen of choice for pharyngeal gonorrhea in adults, adolescents, and children.^{167 179 242 292 508}

Initial treatment of disseminated gonococcal infections†.^{167 221 292 508} Recommended by CDC, AAP, and others as the regimen of choice for initial parenteral treatment in adults, adolescents, and children, especially when meningitis, endocarditis, or conjunctivitis is involved.^{167 242 292 508}

Treatment of epididymitis† (in conjunction with doxycycline) in patients most likely to have infections caused by N. gonorrhoeae and/or C. trachomatis (e.g., in those <35 years of age).^{167 242 292} Drug of choice for empiric treatment.⁵⁰⁸

Treatment of proctitis† (in conjunction with doxycycline) in patients most likely to have infections caused by N. gonorrhoeae and/or C. trachomatis.¹⁶⁷

Parenteral prophylaxis† in neonates born to mothers with documented peripartum gonococcal infection.^{167 292} Considered drug of choice by CDC and AAP.^{167 292}

Treatment of ophthalmia neonatorum† caused by N. gonorrhoeae.^{167 292} The single-dose ceftriaxone regimen is adequate therapy for gonococcal conjunctivitis, but infants with ophthalmia neonatorum should be hospitalized and evaluated for signs of disseminated infection (e.g., sepsis, arthritis, meningitis).^{167 292}

Treatment of disseminated gonococcal infections (e.g., sepsis, arthritis, meningitis) in neonates.^{167 292} Should not be used in neonates who are hyperbilirubinemic (especially those born prematurely) (see Pediatric Use under Cautions);^{1 167 292} AAP suggests cefotaxime is preferred in these neonates.²⁹²

Leptospirosis

Treatment of severe leptospirosis† caused by Leptospira.^{197 292 513 516 518 519}

Leptospirosis is a spirochete infection that may range in severity from a self-limited systemic illness to a severe, life-threatening illness that includes jaundice, renal failure, hemorrhage, cardiac arrhythmias, pneumonitis, and hemodynamic collapse (Weil syndrome).^{292 515 516 517}

Penicillin G generally has been considered the drug of choice for treatment of moderate to severe leptospirosis,^{197 292 513 515 516 519} and doxycycline has been used in less severe infections.^{197 292 516} Cephalosporins (ceftriaxone, cefotaxime), aminopenicillins (ampicillin, amoxicillin), tetracyclines (doxycycline, tetracycline), or macrolides (azithromycin) also have been recommended for severe infections.^{197 292 515 516 517 518 519}

Lyme Disease

Treatment of early neurologic Lyme disease† with acute neurologic manifestations such as meningitis or radiculopathy.^{197 262 277 279 292 353 356 357 358 359 360 361 362 363 365 366 367 477 481} IV ceftriaxone is the drug of choice; alternatives are IV cefotaxime or IV penicillin G.^{277 292 497 498} Although an oral regimen (doxycycline, amoxicillin, cefuroxime axetil) may be effective for early localized or early disseminated Lyme disease associated with erythema migrans in the absence of specific neurologic manifestations or advanced atrioventricular (AV) heart block,^{197 262 277 279 292 353 356 357 358 359 360 361 362 363 365 366 367 477 481} a parenteral regimen usually is recommended when there are acute neurologic manifestations.^{197 262 277 279 292 353 356 357 358 359 360 361 362 363 365 366 367 477 481}

Treatment of Lyme carditis† when a parenteral regimen is indicated.^{262 277 292 497} IV ceftriaxone is the drug of choice; alternatives are IV cefotaxime or IV penicillin G.^{262 277 292 497} Although a parenteral regimen usually is recommended for initial treatment of hospitalized patients, an oral regimen (doxycycline, amoxicillin, cefuroxime axetil) can be used to complete therapy and for the treatment of outpatients.^{262 277 292 497}

Treatment of Lyme arthritis† when a parenteral regimen is indicated.^{262 292 277 497 498} IV ceftriaxone is the drug of choice; alternatives are IV cefotaxime or IV penicillin G.^{262 292 277 497 498} Although the comparative safety and efficacy of oral versus IV anti-infectives for treatment of Lyme arthritis has not been fully evaluated,²⁷⁷ those with concomitant neurologic disease generally should receive a parenteral regimen.^{262 277 292 497 498}

Treatment of late neurologic Lyme disease† affecting the CNS or peripheral nervous system (e.g., encephalopathy, neuropathy).^{277 292} IV ceftriaxone is the drug of choice; alternatives are IV cefotaxime or IV penicillin G.^{277 292}

Neisseria meningitidis Infections

Treatment of invasive infections caused by N. meningitidis.¹ (See Meningitis and Other CNS Infections under Uses.)

Elimination of nasopharyngeal carriage of N. meningitidis†.^{292 374 376} CDC and AAP consider rifampin, ceftriaxone, or ciprofloxacin the drugs of choice for such carriers.^{292 374 376}

Postexposure prophylaxis to prevent meningococcal disease in household or other close contacts of patients with invasive meningococcal disease†.^{1 197 292 374 376}

Outbreak control of meningococcal disease when outbreaks involve small populations (e.g., a small organization such as a single school).³⁷⁷

Nocardiosis

Treatment of nocardiosis† caused by Nocardia.^{197 292 521 522 523 524 525 528}

Co-trimoxazole (fixed combination of sulfamethoxazole and trimethoprim) generally is the drug of choice for treatment of nocardiosis.^{197 292} Other drugs that have been used alone or in combination regimens for treatment of nocardiosis include a sulfonamide alone (sulfamethoxazole [not commercially available in the US], sulfadiazine), amikacin, tetracyclines (minocycline), cephalosporins (ceftriaxone, cefotaxime, cefuroxime), cefoxitin, carbapenems (imipenem or meropenem), fixed combination of amoxicillin and clavulanate, clarithromycin, cycloserine, or linezolid.^{197 292 521 522 524 525 528}

For treatment of invasive nocardiosis or when sulfonamides cannot be tolerated, select anti-infectives based on results of in vitro susceptibility tests.²⁹² If nocardiosis involves the CNS or if the infection is disseminated or overwhelming, some clinicians suggest that amikacin and ceftriaxone be included in the treatment regimen during the first 4–12 weeks of therapy or until there is clinical improvement.²⁹² A regimen of amikacin and ceftriaxone has been effective for the treatment of disseminated N. asteroides infection complicated by cerebral abscess.⁵²²

Pelvic Inflammatory Disease (PID)

Treatment of PID caused by N. gonorrhoeae.^{1 167 242 292 397 398 460 508}

Not considered a drug of choice for parenteral regimens used for treatment of PID.^{167 508} CDC states ceftriaxone may be effective for PID, but is less active than cefotetan or cefoxitin against anaerobic bacteria.¹⁶⁷

When an oral regimen is used for treatment of mild to moderately severe acute PID, CDC recommends a single IM dose of ceftriaxone, cefoxitin (with oral probenecid), or other parenteral third-generation cephalosporin (e.g., cefotaxime, ceftizoxime) given in conjunction with oral doxycycline (with or without oral metronidazole).^{167 508}

Because ceftriaxone (like other cephalosporins) is not active against Chlamydia, concomitant use of a drug active against Chlamydia (e.g., doxycycline) is necessary when these organisms are suspected pathogens.^{1 167}

Pseudomonas aeruginosa Infections

May be effective for treatment of some infections caused by Ps. aeruginosa (see Skin and Skin Structure Infections under Uses).¹

Because many strains of Ps. aeruginosa are only susceptible to high concentrations of ceftriaxone in vitro and because resistant strains of the organism have developed during therapy with the drug,^{120 121 124 127 132 150} ceftriaxone generally should not be used alone in the treatment of any infection where Ps. aeruginosa may be present.^{104 105 106 124 125 128 170 250}

Relapsing Fever

Treatment of relapsing fever† caused by Borrelia recurrentis;²⁶⁴ other drugs (e.g., tetracyclines, penicillin G) usually considered drugs of choice.^{197 292}

Shigella Infections

Treatment of shigellosis† in children caused by susceptible Shigella sonnei or S. flexneri.^{401 402}

Anti-infectives generally indicated in addition to fluid and electrolyte replacement for severe shigellosis.^{292 403} Ceftriaxone is considered a drug of choice for shigellosis when the susceptibility of the isolate is unknown, especially in areas where ampicillin-resistant Shigella have been reported.^{217 292 403}

Syphilis

Alternative for treatment of early syphilis† in patients hypersensitive to penicillin; CDC cautions that optimal dosage and duration of ceftriaxone for this use have not been defined.¹⁶⁷

Alternative for treatment of neurosyphilis† in patients hypersensitive to penicillin.¹⁶⁷

CDC states that IM or IV ceftriaxone may be considered for treatment of infants with clinical evidence of congenital syphilis if there is a penicillin shortage and penicillin G sodium and penicillin G procaine are unavailable.¹⁶⁷ However, the drug should be used in consultation with a specialist in treatment of infants with congenital syphilis and with careful clinical and serologic follow-up.¹⁶⁷

CDC states that data are insufficient to recommend use of ceftriaxone for treatment of early syphilis in pregnant women or pediatric patients hypersensitive to penicillin or for prevention of congenital syphilis and the only acceptable alternatives to penicillin G for patients with late latent syphilis, syphilis of unknown duration, or tertiary syphilis are doxycycline or tetracycline.¹⁶⁷ Use of ceftriaxone in HIV-infected individuals with syphilis has not been adequately studied and such therapy should be undertaken with caution.¹⁶⁷

Because of limited experience with penicillin alternatives, close follow-up is essential if ceftriaxone is used in the treatment of syphilis.¹⁶⁷ If compliance with an alternative regimen cannot be ensured in patients hypersensitive to penicillin, the CDC recommends desensitization and treatment with penicillin G.¹⁶⁷

Typhoid Fever and Other Salmonella Infections

Treatment of typhoid fever (enteric fever) or septicemia caused by Salmonella typhi or S. paratyphi†, including multidrug-resistant strains.^{188 267 406 407 408 409 410 419}

Treatment of infections caused by nontyphi Salmonella, including bacteremia or osteomyelitis caused by S. typhimurium.^{410 418}

Treatment of gastroenteritis caused by Salmonella (e.g., S. enteritidis, S. typhimurium) in individuals with severe Salmonella gastroenteritis and in those who are at increased risk of invasive disease.^{197 217 292 412}

Whipple's Disease

Treatment of Whipple’s disease†, a progressive systemic infection caused by Tropheryma whippelii.^{383 384 385 386}

Empiric Therapy in Febrile Neutropenic Patients

Empiric anti-infective therapy of presumed bacterial infections in febrile neutropenic adults or pediatric patients†; used in conjunction with an aminoglycoside.^{387 388 390 437}

Ceftriaxone monotherapy may not provide adequate coverage against some potential pathogens (e.g., Ps. aeruginosa) and such monotherapy generally is not recommended for empiric anti-infective therapy in febrile neutropenic patients.^{390 435 436}

Perioperative Prophylaxis

Perioperative prophylaxis to reduce the incidence of infection in patients undergoing contaminated or potentially contaminated surgical procedures,¹ including cholecystectomy,^{1 147 152 294 295 296 297 298 449} intra-abdominal surgery,^{152 450} or vaginal or abdominal hysterectomy,^{1 154} and in those undergoing clean surgical procedures in which the development of infection at the surgical site would represent a serious risk,¹ including coronary artery bypass,¹ open heart surgery,^{67 105 151} thoracic surgery,⁴⁵² or orthopedic surgery.^{105 153} The drug also has been used perioperatively in patients undergoing transurethral resection of the prostate†.^{148 155 451}

Other cephalosporins or cephamycins (cefazolin, cefuroxime, cefotetan, cefoxitin) are the preferred drugs for perioperative prophylaxis.^{104 106 164 168 175 236 306} Ceftriaxone and other third generation cephalosporins usually not used for perioperative prophylaxis since they are expensive, some are less active against staphylococci than cefazolin, they have a spectrum of activity wider than necessary for organisms encountered in elective surgery, and their use for prophylaxis promotes emergence of resistant organisms.³⁰⁶

Prophylaxis in Sexual Assault Victims

Empiric anti-infective prophylaxis in sexual assault victims†; used in conjunction with oral metronidazole and oral azithromycin or doxycycline.^{167 292}

Prophylaxis Following Bite Wounds

Prophylaxis following a bite wound† (human or animal).²⁹²

Rocephin Dosage and Administration

Administration

Administer by IV infusion or deep IM injection.^{1 180 307 501 502}

The commercially available premixed ceftriaxone injection (frozen) should be used only for IV infusion.³⁰⁷

Do not use diluents containing calcium (e.g. Ringer's/lactated Ringer's injection, Hartmann's injection) to reconstitute or further dilute ceftriaxone because a precipitate can form.^{1 180 507 511 529}

Because precipitation of ceftriaxone-calcium can occur, ceftriaxone must not be admixed with calcium-containing solutions and must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition, even via different infusion lines at different sites in any patient (irrespective of age).^{1 507 510 511 529} (See Interaction with Calcium-containing Products under Cautions.)

Ceftriaxone is contraindicated in neonates (≤28 days of age) if they are receiving (or expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition.^{1 529} In adults and pediatric patients older than 28 days of a